Pre-Clinical Detection
Non-invasive patient stratification for pharmaceutical research and pre-clinical studies via Retinal Hyperspectral Imaging..
Two Layers of Intelligence
Whether you are a Pharmaceutical Company or specialized Alzheimer’s Center we offer a precision tool to identify the right candidates earlier and accurately.
1. Clinical ML Engine (Screening)
Analyzes routine clinical data (EHR) and cognitive assessments to rapidly filter massive patient populations, identifying at-risk individuals for trial recruitment at minimal cost.
2. Retinal HSI (Biomarker)
Hyperspectral Imaging detects spectral signatures of beta-amyloid aggregates in the retina, providing a scalable, non-invasive biomarker for precise inclusion criteria.
Built for Pharma & Clinical Research
De-risk your clinical trials by recruiting the right patients, earlier.
🎯 Precise Recruitment
Drastically reduce screening failures by identifying pre-symptomatic patients with high biological risk before expensive PET/CSF tests.
📊 Patient Stratification
Segment trial cohorts based on quantitative spectral biomarkers representing disease stage and progression risk.
📈 Longitudinal Monitoring
Non-invasive, repeatable scans allow for frequent monitoring of disease progression and potential therapeutic effects during trials.
The Retinal Window
As an extension of the CNS, the retina offers a unique opportunity to visualize neurodegenerative changes non-invasively using advanced optics.
less than 1 Second per eye scan.
High-throughput screening for efficient patient processing.
Partner with us for your next study
Explore how our HSI platform can optimize your clinical trial pipeline.